Ph II Adjuvant Carboplatin/Docetaxel in Curatively Resected Stage I-IIIA NSCLC

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically confirmed non-small cell lung cancer
• •* Stage I-IIIA disease
• •Must have undergone a complete resection
• •Must begin adjuvant chemotherapy within 8 weeks of surgical resection
• •PATIENT CHARACTERISTICS:
• •Eastern Cooperative Oncology Group (ECOG) performance status 0-1
• •Absolute neutrophil count ≥ 1,500/mm\^3
• •Hemoglobin ≥ 8.0 g/dL
• •Platelet count ≥ 100,000/mm\^3
• •Serum creatinine normal OR creatinine clearance ≥ 40 mL/min
• •Bilirubin normal
• •Alkaline phosphatase (AP), Aspartate aminotransferase (AST), and Alanine transaminase (ALT) must meet 1 of the following criteria:
• •* AP normal AND AST and ALT ≤ 5 times upper limit of normal (ULN)
• •* AP ≤ 2.5 times ULN AND AST and ALT ≤ 1.5 times ULN
• •* AP ≤ 5 times ULN AND AST and ALT normal
• •Negative pregnancy test
• •Fertile patients must use effective contraception during and for at least 3 months after study therapy